(Alliance News) - Concerns are increasing over the way Oxford University and AstraZeneca PLC have handled the early readout from trials of their coronavirus vaccine candidate, the Financial Times reported on Wednesday.
The results were hailed a success for showing an average efficacy of 70%, a figure reached by pooling the results from cohorts on two different dosing regimens.
AstraZeneca on Monday said one dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart. Another dosing regimen showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.
But on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the US government's funding programme for vaccine development, disclosed that the subgroup that scored 90% was limited to people aged 55 or below, a demographic with lower risk of developing severe Covid-19, FT reported.
Oxford and AstraZeneca did not disclose the age breakdown on Monday, when results were released.
AstraZeneca shares closed 2.4% lower on Wednesday in London at 7,810.00 pence each. The stock is down 6.0% so far this week.
By Evelina Grecenko; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.